Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-10-31
2006-10-31
Schnizer, Richard (Department: 1635)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C536S023500, C435S320100, C435S252300, C435S325000
Reexamination Certificate
active
07129061
ABSTRACT:
The present invention relates to Tumor necrosis factor related ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.
REFERENCES:
patent: 4921698 (1990-05-01), Shirai et al.
patent: 5200313 (1993-04-01), Carrico
patent: 95/14772 (1995-06-01), None
Degli-Esposti, Journal of Leukocyte Biology, 65:535-542, 1999.
Darnay et al., Ann. Rheum. Dis., 58(Suppl. I):12-I13, 1999.
Agrawal, TIBTECH, 14:376-387, 1996.
Branch, TIBS, 23:45-50, 1998.
Verma et al., Nature, 18:239-242, 1997.
Orkin et al., in Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 7, 1995.
Rudinger; Characteristics of the amino acids as components of a peptide hormone sequence, 1976, Peptide Hormones, 1,6.
Ngo et al.; Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox, 1994, Protein Folding Problem and Tertiary Structure Prediction: 491-494.
Dermer (BioTechnology (1994) 12: 320).
Miller et al (J. Mol. Biol. 131: 191-222, 1979).
Bowie et al (Science 247:1306-1310, 1990).
Abreu-Martin et al., 1995, J. of Immunol. 155:4147-4154, “Divergent Induction of Apoptosis and IL-8 Secretion in HT-29 Cells in Response to TNF-Alpha and Ligation of Fas Antigen”.
Agematsu et al., 1995, Eur. J. Immunol. 25:2825-2829, “CD27/CD70 Interaction Directly Drives B Cell IgG and IgM Synthesis”.
Allen et al., 1993, Science 259:990-993, “CD40 Ligand Gene Defects Responsible for X-Linked Hyper-IgM Syndrome”.
Amakawa et al., 1996, Cell 84:551-562, “Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30-Deficient Mice”.
Badley et al., 1996, Journal of Virology 70:199-206, “Upregulation of Fas Ligand Expression by Human Immunodeficiency Virus in Human Macrophages Mediates Apoptosis of Uninfected T Lymphocytes”.
Banks et al., 1995, J. of Immunol. 155:1685-1693, “Lymphotoxin-Alpha-Deficient Mice. Effects on Secondary Lymphoid Organ Development and Humoral Immune Responsiveness”.
Biancone et al., 1995, Kidney International 48:458-468, “Inhibition of the CD40-CD40ligand Pathway Prevents Murine Membranous Glomerulonephritis”.
Bodmer et al., 1997, Immunity 6:79-88, TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95).
Brojatsch et al., 1996, Cell 87:845-855, “CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis”.
Browning et al., 1989, J. of Immunol. 143:1859-1867, “Studies on the differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines”.
Browning et al., 1991, J. of Immunol. 147:1230-1237, “Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma”.
Browning et al., 1993, Cell 72:847-856, “Lymphotoxin Beta, A Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface”.
Browning et al., 1995, J. of Immunol. 154:33-46, “Characterization of Surface Lymphotoxin Forms”.
Browning et al., 1996, J. of Biological Chemistry 271:8618-8626, “Preparation and Characterization of Soluble Recombinant Heterotrimeric Complexes of Human Lymphotoxins Alpha and Beta”.
Browning, et al., 1996, J. Exp. Med. 183:867-878, “Signaling through the Lymphotoxin Beta Receptor Induces the Death of Some Adenocarcinoma Tumor Lines”.
Bucher, P. and A. Bairoch, 1994, “A Generalized Profile Syntax for Biomolecular Sequence Motifs and its Function in Automatic Sequence Interpretation”, Proc. Second International Conference on Intelligent Systems for Molecular Biology, Altman, Brutlag, Karp, Lathrop, Searls (Eds.), pp. 53-61.
Castro et al., 1996, Immunity 6:617-627, “Fas Modulation of Apoptosis during Negative Selection of Thymocytes”.
Chen, Y.A. and A.B. Shyu, 1995, Trends in Biol. Sci. 20:465-470, “AU-Rich Elements: Characterization and Importance in mRNA Degradation”.
Chichportiche et al., 1995, Biochemical and Biophysical Research Communications 209:1076-1081, “Identification in Mouse Macrophages of a New 4Kb mRNA Present in Hematopoitec Tissues, Which Shares a Short Nucleotide Sequence with Erythropoietin mRNA”.
Chinnaiyan et al., 1996, Science 274:990-992, “Signal Transduction by DR3 a Death Domain-Containing Receptor Related to TNFR-1 and CD95”.
Clark et al., 1992, “TNF in Malaria”, in Tumor Necrosis Factors. The Molecules and Their Emerging Role in Medicine, B. Beutler (Ed.), Raven Press, NY, pp. 303-328.
Cleary et al., 1995, J. of Immunol. 155:3329-3337, “Opposing Roles of CD95 (Fas/APO-1) and CD40 in the Death and Rescue of Human Low Density Tonsillar B Cells”.
Crowe et al., 1994, Science 264:707-710, “A Lymphotoxin-beta-Specific Receptor”.
Cwirla et al., 1990, Proc. Natl. Acad. Sci. USA 87:6378-6382, “Peptides on Phage: A Vast Library of Peptides for Identifying Ligands”.
De Togni et al., 1994, Science 264:703-707, “Abnormal Development of Peripheral Lymphoid Organs in Mice deficient in Lymphotoxin”.
DeBenedette et al., 1995, J. Exp. Med. 181:985-992, “Role of 4-1BB Ligand in Costimulation of T Lymphocyte Growth and its Upregulation on M12 B Lymphomas by cAMP”.
Degli-Esposti et al., 1997, J. of Immunol. 158:1756-1762, “Activation of the Lymphotoxin Beta Receptor by Cross-Linking Induces Chemokine Production and Growth Arrest in A375 Melanoma Cells”.
Devlin et al., 1990, Science 249:404-406, “Random Peptide Libraries: A Source of Specific Protein Binding Molecules”.
Eck et al., 1992, J. of Biological Chemistry 267:2119-2122, “The Structure of Human Lymphotoxin (Tumor Necrosis Factor-Beta) at 1.9-A Resolution”.
Falk et al., 1992, Blood 79:3300-3306, “Expression of the APO-1 Antigen in Burkitt Lymphoma Cell Lines Correlates With a Shift Towards a Lymphoblastoid Phenotype”.
Fox, David, 1995, American J. of Medicine 99:82-88, “Biological Therapies: A Novel Approach to the Treatment of Autoimmune Disease”.
Foy et al., 1996, Annu. Rev. Immunol. 14:591-617, “Immune Regulation by CD40 and Its Ligand GP39”.
Funakoshi et al., 1994, Blood 83:2787-2794, “Inhibition of Human B0Cell Lymphoma Growth by CD40 Stimulation”.
Galle et al., 1995, J. Exp. Med. 182:1223-1230, “Involvement of the CD95 (APO-1/Fas) Receptor and Ligand in Liver Damage”.
Gauchet et al., 1993, Federation of European Biochemical Societies Letters 315:259-266, “Human CD40-Ligand: Molecular Cloning, Cellular Distribution and Regulation of Expression by Factors Controlling IgE Production”.
Goeddel et al., 1986, Cold Spring Harbor Symposia on Quantitative Biology L1:597-609, “Tumor Necrosis Factors: Gene Structure and Biological Activities”.
Goodwin et al., 1993, Cell 73:447-456, “Molecular and Biological Characterization of a Ligand for CD27 Defines a New Family of Cytokines with Homology to Tumor Necrosis Factor”.
Goodwin et al., 1993, Eur. J. Immunol. 23:2631-2641, “Molecular Cloning of a Ligand for the Inducible T Cell Gene 4-1BB: A Member of an Emerging Family of Cytokines with Homology to Tumor Necrosis Factor”.
Grau et al., 1992, “TNF and Mycobacteria”, in Tumor Necrosis Factors. The Molecules and Their Emerging Role in Medicine, B. Beutler (Ed.), Raven Press, NY, pp. 329-340.
Gruss et al., 1994, Blood 83:2045-2056, “Pleiotrophic Effects of the CD30 Ligand on CD30-Expressing Cells and Lymphoma Cell Lines”.
Gruss, Hans-Jurgen and Steven K. Dower, 1995, Blood 85:3378-3404, “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas”.
Hess, Sigrun and Hartmut Engelmann, 1996, J. Exp. M
Browning Jeffrey
Chichportiche Yves
Biogen Idec MA Inc.
Fish & Richardson P.C.
Schnizer Richard
The Faculty of Medicine of the University of Geneva
LandOfFree
Tumor necrosis factor related ligand does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor necrosis factor related ligand, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor necrosis factor related ligand will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3636030